Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Isis; Cold Spring Harbor Lab; Merck; and More


Title: Environment-Responding siRNA Carrier Using Disulfide Cross-Linked Polymeric Micelle

Patent Number: 8,153,110

Filed: Nov. 22, 2007

Lead Inventor: Kazunori Kataoka, University of Tokyo

The invention comprises an “siRNA-encapsulating polymeric micelle complex having high monodispersibility and structural stability and ... the ability [to transport] siRNA into a cell,” the patent's abstract states. “Further disclosed are a nucleic acid delivery device, a nucleic acid delivery kit, a pharmaceutical composition, and a gene therapy agent, each of which uses the complex. The polyion complex is characterized by ... a block co-polymer composed of a polyethylene glycol moiety ... a polycation moiety having a thiol group as a side chain at the terminus, and [an] siRNA.”

Title: Composition and Methods for the Pulmonary Delivery of Nucleic Acids

Patent Number: 8,153,602

Filed: May 10, 1999

Lead Inventor: Frank Bennett, Isis Pharmaceuticals

The invention, the patent's abstract states, relates to “compositions and methods for the pulmonary delivery of nucleic acids, particularly oligonucleotides. In one preferred embodiment, the compositions and methods of the invention are utilized to affect the pulmonary delivery of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic or prophylactic purposes.”

Title: Methods and Compositions for RNA Interference

Patent Number: 8,153,776

Filed: Aug. 20, 2007

Lead Inventor: Gregory Hannon, Cold Spring Harbor Laboratory

The invention comprises “methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double-stranded RNA, such as a hairpin RNA,” the patent's abstract states. “The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited.”

Title: RNA Interference-Mediated Inhibition of Vascular Cell Adhesion Molecule Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 8,153,778

Filed: Jan. 26, 2010

Lead Inventor: James McSwiggen, Merck

“This invention relates to compounds, compositions, and methods useful for modulating vascular cell adhesion molecule gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of vascular cell adhesion molecule gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the ... invention features small nucleic acid molecules ... and methods used to modulate the expression of vascular cell adhesion molecule genes, such as vascular cell adhesion molecule 1.”

Title: Small Molecule Inhibitors of RNA Silencing

Application Number: 20120077804

Filed: July 24, 2008

Inventor: Shou-Wei Ding, University of California, Oakland

The invention, the patent application's abstract states, provides “compositions and formulations that contain active compounds as RNAi inhibitors. These compositions and formulations are useful for controlling insects and pests including mosquitoes and agricultural pests.”

Title: Method and Compositions for Inhibiting Tumorigenesis

Application Number: 20120083419

Filed: Nov. 7, 2008

Lead Inventor: Ariel Ruiz i Altaba, University of Geneva Medical School

The invention, the patent application's abstract states, relates to “compounds, small interfering RNAs, and compositions and methods of inhibiting tumorigenesis and methods of inhibiting tumor cell growth and proliferation using agents that inhibit the hedgehog and GLI signaling pathway, including agents that inhibit GLI synthesis and/or function. The ... invention also relates to particular biomarkers that can be used in the diagnosis and prognosis of prostate cancer. Methods of treating cancer, including prostate cancer, are also provided using small organic compounds, siRNAs, and blocking antibodies that inhibit or block the SHH/GLI pathway.”

Title: Methods for Producing microRNAs

Application Number: 20120084872

Filed: June 7, 2011

Lead Inventor: Ross Dickins, Cold Spring Harbor Laboratory

“The invention relates to recombinant vectors for inducible and/or tissue-specific expression of double-stranded RNA molecules that interfere with the expression of a target gene,” according to the patent application's abstract. “In certain embodiments, the invention relates to the use of tetracycline-responsive RNA polymerase II promoters to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals expressing inducible, reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.”

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more